Dry powder formulations for nasal vaccine delivery offer versatile advantages compared to liquid formulations, such as increased storage stability and simplified administration. The objective of the present study was the development of a dry powder nasal vaccine formulation making use of antigen-loaded chitosan microparticles. Special emphasis was put on the development and characterization of a formulation which can realistically be used in humans by means of a nasal dry powder sprayer. Microparticles of chitosan with bovine serum albumin as model antigen were produced by spray drying and showed a particle size of about 3 μm. In order to improve nasal deposition and dispersibility, powder blends with low separation tendency were prepared. 

More